<SEC-DOCUMENT>0001104659-22-080032.txt : 20220715
<SEC-HEADER>0001104659-22-080032.hdr.sgml : 20220715
<ACCEPTANCE-DATETIME>20220715080612
ACCESSION NUMBER:		0001104659-22-080032
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220711
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220715
DATE AS OF CHANGE:		20220715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		221084298

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2218235-2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220711">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_syn_syntheticbiologics.com_20220711 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20220711_20220711 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_12/31 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">12/31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20220711.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-11to2022-07-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-11</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20220711__20220711_zkILNkfdZ8Og"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_905_edei--DocumentPeriodEndDate_c20220711__20220711_zDzlUsQjeqJ6"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 11, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityRegistrantName_c20220711__20220711_z8aRty5AOsab"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityRegistrantName">SYNTHETIC BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220711__20220711_zm7TlRJ1FwRb"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20220711__20220711_zpiRN9gSD1F1"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20220711__20220711_zg46ioZFAzth"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20220711__20220711_zHioIKPu8Ggg"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20220711__20220711_zxSc7F0i68O7"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20220711__20220711_zqTdeb25zKw4"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220711__20220711_zQPgNGNQu114"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20220711__20220711_z6wr7YMFNsa5"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_904_edei--CityAreaCode_c20220711__20220711_zx7F2fwTMamj"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20220711__20220711_z9nGpezu8T39"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_900_edei--WrittenCommunications_c20220711__20220711_zc84ae3xzWy9"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90A_edei--SolicitingMaterial_c20220711__20220711_zYCfAmxBfL38"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20220711__20220711_zauTz5MUcc9j"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20220711__20220711_zG0bU3NoHbIj"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20220711__20220711_zTOeu6cheFj7"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220711__20220711_zmH4Ys7i4407"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" name="dei:TradingSymbol">SYN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20220711__20220711_zAR3gw5x3rga"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20220711__20220711_zMmHt6uz2N45"><ix:nonNumeric contextRef="From2022-07-11to2022-07-11" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 3.03</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Modification to Rights of Security Holders.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, the Board of Directors of Synthetic
Biologics, Inc., a Nevada corporation (the &#8220;Company&#8221;), approved a reverse stock split of the Company&#8217;s authorized, issued
and outstanding shares of common stock, par value $0.001 per share, at a ratio of 1-for-10. On July 15, 2022, the Company issued a press
release announcing the Reverse Stock Split. A copy of the press release is filed herewith as <span style="text-decoration: underline">Exhibit 99.1</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 1in"><b>Item 5.03.</b></td>
    <td><b>Amendments to Articles of Incorporation or
    Bylaws; Change in Fiscal Year.</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Reverse Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 11, 2022, the
Board of Directors of the Company approved a reverse stock split of the Company&#8217;s authorized, issued and outstanding shares of common
stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every ten (10) shares of common stock (the &#8220;Reverse
Stock Split&#8221;). The Company anticipates that the Reverse Stock Split will be effective at 12:01 a.m., Eastern Time, on July 25, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Split Adjustment;
Treatment of Fractional Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a result of the Reverse
Stock Split, each ten (10) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common stock
without any action on the part of the holders, and the number of outstanding shares common stock will be reduced from 158,437,840 shares
to 15,843,784 shares (subject to rounding of fractional shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No fractional shares
will be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares because
they hold a number of pre-reverse stock split shares of the Company&#8217;s common stock not evenly divisible by 10, will, in lieu of
a fractional share, be entitled the number of shares rounded up to the nearest whole share. The Company will issue one whole share of
the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse
Stock Split. As a result, no fractional shares will be issued in connection with the Reverse Stock Split and no cash or other consideration
will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>NYSE American Compliance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Reverse Stock Split
is being effected to <span style="color: #333333; background-color: white">is being effected to ensure that the Company can meet the per
share price requirements of the NYSE American, the Company's current listing exchange</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Trading Symbol; New
CUSIP</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">After the Reverse Stock
Split, the trading symbol for the Company&#8217;s common stock will continue to be &#8220;SYN.&#8221; The new CUSIP number for the Company&#8217;s
common stock following the Reverse Stock Split is 87164U409.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended and Restated Bylaws</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, the Board of Directors of the
Company amended and restated the Company&#8217;s by-laws (the &#8220;Amended By-laws&#8221;), effective immediately in order to amend
the quorum requirement of Article 1.05 of the by-laws, such that except where otherwise provided by law, the presence in person or by
proxy of the holders of shares of stock having one-third (1/3) of the voting power of the shares of stock entitled to vote at the meeting
shall constitute a quorum for the transaction of business at all meetings of the stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description is qualified in its
entirety by the Amended By-laws which are attached hereto as <span style="text-decoration: underline">Exhibit 3.1</span> and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 15, 2022, the
Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as <span style="text-decoration: underline">Exhibit 99.1</span>
to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b>Item 9.01.</b></td><td style="text-align: justify"><b>Financial Statements and Exhibits.</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>Exhibit<br />
  No.</b></td>
  <td style="padding-bottom: 1pt; width: 2%"><b>&#160;</b></td>
  <td style="padding-bottom: 1pt; width: 88%"><p style="margin-top: 0; margin-bottom: 0"><b>&#160;</b></p>
                         <p style="border-bottom: Black 1pt solid; text-align: center"><b>Description</b></p></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><a href="tm2218235d2_ex3-1.htm">3.1</a></td>
  <td>&#160;</td>
  <td><a href="tm2218235d2_ex3-1.htm">Amended and Restated By-laws of Synthetic Biologics, Inc.</a></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><a href="tm2218235d2_ex99-1.htm">99.1</a></td>
  <td>&#160;</td>
  <td><a href="tm2218235d2_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated July 15, 2022</span></a></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>104</td>
  <td>&#160;</td>
  <td>Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: July 15, 2022</span></td>
    <td colspan="3" style="padding-right: 2.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 5%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 5%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 40%; padding-right: 0.8pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">and Chief Financial Officer</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4d6GSXDhVxyhgi3hYXpbg1I60/eyTf0m5DDIGQnPPlCDERG1rrGhnOyzKHIzZtrRxCiVdkNBf0jmy7S8HPEm/aOlbGDesPzMgz6JnZdKH8fXA+tcUqhWgeyiSMJURJKhMo9iLo9YzMVVdonFY1KFNBwdSyRqe4Gz8c1ZsMNd2QdEK2mkwKchqN8gfiSMZwoKd6Ed8t5HkmgslQgdgwPdo+5mEdNbCqsfFZdkT/HXwB5GpJJA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2218235d2_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED BY-LAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Nevada corporation)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adopted and Effective:&nbsp;&nbsp;July 11, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp; <B>ARTICLE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCKHOLDERS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.01 &nbsp; <U>Annual Meetings</U>
.. An annual meeting of stockholders shall be held for the election of Directors at such date, time and place either within or without
the State of Nevada as may be designated by the Board of Directors from time to time. Any other proper business may be transacted at the
annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.02 &nbsp; <U>&nbsp;&nbsp;Special
Meetings</U> . Special meetings of stockholders may be called at any time by the Chairman of the Board, if any, the Vice Chairman of the
Board, if any, or the President to be held at such date, time and place either within or without the State of Nevada as may be stated
in the notice of the meeting. A special meeting of stockholders shall be called by the Secretary within 120 days of his or her receipt
of a written request, stating the purpose of the meeting, of stockholders who together own of record a majority of the outstanding shares
of each class of stock entitled to vote at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.03 &nbsp; <U>Notice of Meetings</U>
.. Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which
shall state the place, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting
is called. Unless otherwise provided by law, the written notice of any meeting shall be given not less than ten nor more than sixty days
before the date of the meeting to each stockholder entitled to vote at such meeting. If mailed, such notice shall be deemed to be given
when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&rsquo;s address as it appears
on the records of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.04 &nbsp; <U>Adjournments</U>
.. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, and notice
need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is
taken. At the adjourned meeting the Corporation may transact any business which might have been transacted at the original meeting. If
the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice
of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.05 &nbsp; <U>Quorum</U>
.. At each meeting of stockholders, except where otherwise provided by law, the presence in person or by proxy of the holders of shares
of stock having one-third (1/3) of the voting power of the shares of stock entitled to vote at the meeting shall be necessary and sufficient
to constitute a quorum. In the absence of a quorum the stockholders so present may, by majority vote, adjourn the meeting from time to
time in the manner provided by Section 1.04 of these by-laws until a quorum shall attend. Shares of its own capital stock belonging on
the record date for the meeting to the Corporation or to another corporation, if a majority of the shares entitled to vote in the election
of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted
for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation to vote stock, including but not
limited to its own stock, held by it in a fiduciary capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.06 &nbsp; <U>Organization</U>
.. Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in the absence of the Chairman of the Board
by the Vice Chairman of the Board, if any, or in the absence of the Vice Chairman of the Board by the President, or in the absence of
the President by a Vice President, or in the absence of the foregoing persons by a chairman designated by the Board of Directors, or in
the absence of such designation by a chairman chosen at the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary,
shall act as secretary of the meeting, but in the absence of the Secretary and any Assistant Secretary the chairman of the meeting may
appoint any person to act as secretary of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.07 &nbsp; <U>Voting; Proxies</U>
.. Unless otherwise provided in the articles of incorporation, each stockholder entitled to vote at any meeting of stockholders shall be
entitled to one vote for each share of stock held by such stockholder which has voting power upon the matter in question. If the articles
of incorporation provides for more or less than one vote for any share on any matter, every reference in these by-laws to a majority or
other proportion of stock shall refer to such majority or other proportion of the votes of such stock. Each stockholder entitled to vote
at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person
or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless
the proxy provides for a longer period. A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only
as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which
is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or another duly
executed proxy bearing a later date with the Secretary of the Corporation. Voting at meetings of stockholders need not be by written ballot
and need not be conducted by inspectors unless the holders of a majority of the outstanding shares of all classes of stock entitled to
vote thereon present in person or by proxy at such meeting shall so determine. At all meetings of stockholders for the election of directors
a plurality of the votes cast shall be sufficient to elect. With respect to other matters, unless otherwise provided by law or by the
articles of incorporation or these by-laws, the affirmative vote of the holders of a majority of the shares of all classes of stock present
in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders, provided
that (except as otherwise required by law or by the articles of incorporation) the Board of Directors may require a larger vote upon any
such matter. Where a separate vote by class is required, the affirmative vote of the holders of a majority of the shares of each class
present in person or represented by proxy at the meeting shall be the act of such class, except as otherwise provided by law or by the
articles of incorporation or these by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.08 &nbsp; <U>Fixing Date
for Determination of Stockholders of Record</U> . In order that the Corporation may determine the stockholders entitled to notice of or
to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting,
or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in
respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix,
in advance, a record date, which shall not be more than sixty nor less than ten days before the date of such meeting, nor more than sixty
days prior to any other action. If no record date is fixed: (1) the record date for determining stockholders entitled to notice of or
to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or,
if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (2) the record date for
determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action by the Board
is necessary, shall be the day on which the first written consent is expressed; and (3) the record date for determining stockholders for
any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto. A determination
of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting;
provided, however, that the Board may fix a new record date for the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.09 &nbsp; <U>List of Stockholders
Entitled to Vote</U> . The Secretary shall prepare and make, at least ten days before every meeting of stockholders, a complete list of
the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the
number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose
germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within
the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the
place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole
time thereof and may be inspected by any stockholder who is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.10 &nbsp; <U>Consent of
Stockholders in Lieu of Meeting</U> . Any action required by law to be taken at any annual or special meeting of stockholders of the Corporation,
or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior
notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock
having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares
entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous
written consent shall be given to those stockholders who have not consented in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 9pt"><B>ARTICLE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 9pt"><B><U>BOARD OF DIRECTORS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.01 &nbsp; <U>Powers; Number;
Qualifications</U> . The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors,
except as may be otherwise provided by law or in the articles of incorporation. The Board shall consist of one or more members, the number
thereof to be determined from time to time by the Board. Directors need not be stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.02 &nbsp; <U>Election; Term
of Office; Resignation; Removal; Vacancies</U> . Each director shall hold office until the annual meeting of stockholders next succeeding
his or her election and until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any director
may resign at any time upon written notice to the Board of Directors or to the President or the Secretary of the Corporation. Such resignation
shall take effect at the time specified therein, and unless otherwise specified therein no acceptance of such resignation shall be necessary
to make it effective. Any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority
of the shares then entitled to vote at an election of directors; except that, if the articles of incorporation provides for cumulative
voting and less than the entire Board is to be removed, no director may be removed without cause if the votes cast against his or her
removal would be sufficient to elect him or her if then cumulatively voted at an election of the entire Board, or, if there be classes
of directors, at an election of the class of directors of which he or she is a part. Whenever the holders of any class or series of stock
are entitled to elect one or more directors by the provisions of the articles of incorporation, the provisions of the preceding sentence
shall apply, in respect to the removal without cause of a director or directors so elected, to the vote of the holders of the outstanding
shares of that class or series and not to the vote of the outstanding shares as a whole. Unless otherwise provided in the articles of
incorporation or these by-laws, vacancies and newly created directorships resulting from any increase in the authorized number of directors
elected by all of the stockholders having the right to vote as a single class or from any other cause may be filled by a majority of the
directors then in office, although less than a quorum, or by the sole remaining director. Whenever the holders of any class or classes
of stock or series thereof are entitled to elect one or more directors by the provisions of the articles of incorporation, vacancies and
newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such class or classes
or series thereof then in office, or by the sole remaining director so elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.03 &nbsp; <U>Regular Meetings</U>
.. Regular meetings of the Board of Directors may be held at such places within or without the State of Nevada and at such times as the
Board may from time to time determine, and if so determined notice thereof need not be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.04 &nbsp; <U>Special Meetings</U>
.. Special meetings of the Board of Directors may be held at any time or place within or without the State of Nevada whenever called by
the Chairman of the Board, if any, by the Vice Chairman of the Board, if any, by the President or by any two directors. Reasonable notice
thereof shall be given by the person or persons calling the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.05 &nbsp; <U>Participation
in Meetings by Conference Telephone Permitted</U> . Unless otherwise restricted by the articles of incorporation or these by-laws, members
of the Board of Directors, or any committee designated by the Board, may participate in a meeting of the Board or of such committee, as
the case may be, by means of conference telephone or similar communications equipment by means of which all persons participating in the
meeting can hear each other, and participation in a meeting pursuant to this by-law shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.06 &nbsp; <U>Quorum; Vote
Required for Action</U> . At all meetings of the Board of Directors one-third of the entire Board shall constitute a quorum for the transaction
of business. The vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board unless
the articles of incorporation or these by-laws shall require a vote of a greater number. In case at any meeting of the Board a quorum
shall not be present, the members of the Board present may adjourn the meeting from time to time until a quorum shall attend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.07 &nbsp; <U>Organization</U>
.. Meetings of the Board of Directors shall be presided over by the Chairman of the Board, if any, or in the absence of the Chairman of
the Board by the Vice Chairman of the Board, if any, or in the absence of the Vice Chairman of the Board by the President, or in their
absence by a chairman chosen at the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary, shall act as secretary
of the meeting, but in the absence of the Secretary and any Assistant Secretary the chairman of the meeting may appoint any person to
act as secretary of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.08 &nbsp; <U>Action by Directors
Without a Meeting</U> . Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof,
may be taken without a meeting if all members of the Board or of such committee, as the case may be, consent thereto in writing, and the
writing or writings are filed with the minutes of proceedings of the Board or committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.09 &nbsp; <U>Compensation
of Directors</U> . The Board of Directors shall have the authority to fix the compensation of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMITTEES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.01 &nbsp; <U>Committees</U>
.. The Board of Directors may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee
to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any
committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a
member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member
or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent
or disqualified member. Any such committee, to the extent provided in the resolution of the Board, shall have and may exercise all the
powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the
Corporation to be affixed to all papers which may require it; but no such committee shall have power or authority in reference to amending
the articles of incorporation, adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange
of all or substantially all of the Corporation&rsquo;s property and assets, recommending to the stockholders a dissolution of the Corporation
or a revocation of dissolution, removing or indemnifying directors or amending these by-laws; and, unless the resolution expressly so
provides, no such committee shall have the power or authority to declare a dividend or to authorize the issuance of stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.02 &nbsp; <U>Committee Rules</U>
.. Unless the Board of Directors otherwise provides, each committee designated by the Board may adopt, amend and repeal rules for the conduct
of its business. In the absence of a provision by the Board or a provision in the rules of such committee to the contrary, a majority
of the entire authorized number of members of such committee shall constitute a quorum for the transaction of business, the vote of a
majority of the members present at a meeting at the time of such vote if a quorum is then present shall be the act of such committee,
and in other respects each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article
II of these by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>OFFICERS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.01 &nbsp; <U>Officers; Election</U>
.. As soon as practicable after the annual meeting of stockholders in each year, the Board of Directors shall elect a President and a Secretary,
and it may, if it so determines, elect from among its members a Chairman of the Board and a Vice Chairman of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.02 &nbsp; The Board may
also elect one or more Vice Presidents, one or more Assistant Vice Presidents, one or more Assistant Secretaries, a Treasurer and one
or more Assistant Treasurers and such other officers as the Board may deem desirable or appropriate and may give any of them such further
designations or alternate titles as it considers desirable. Any number of offices may be held by the same person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.03 &nbsp; <U>Term of office;
Resignation; Removal; Vacancies</U> . Except as otherwise provided in the resolution of the Board of Directors electing any officer, each
officer shall hold office until the first meeting of the Board after the annual meeting of stockholders next succeeding his or her election,
and until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any officer may resign at
any time upon written notice to the Board or to the President or the Secretary of the Corporation. Such resignation shall take effect
at the time specified therein, and unless otherwise specified therein no acceptance of such resignation shall be necessary to make it
effective. The Board may remove any officer with or without cause at any time. Any such removal shall be without prejudice to the contractual
rights of such officer, if any, with the Corporation, but the election of an officer shall not of itself create contractual rights. Any
vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled for the unexpired portion
of the term by the Board at any regular or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.04 &nbsp; <U>Chairman of
the Board</U> . The Chairman of the Board, if any, shall preside at all meetings of the Board of Directors and of the stockholders at
which he or she shall be present and shall have and may exercise such powers as may, from time to time, be assigned to him or her by the
Board and as may be provided by law.&nbsp;&nbsp;The Chairman of the Board may be, but also need not be, an officer of the Corporation
or employed in an executive or any other capacity by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.05 &nbsp; <U>Vice Chairman
of the Board</U> . In the absence of the Chairman of the Board, the Vice Chairman of the Board, if any, shall preside at all meetings
of the Board of Directors and of the stockholders at which he or she shall be present and shall have and may exercise such powers as may,
from time to time, be assigned to him or her by the Board and as may be provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.06 &nbsp; <U>President</U>
.. In the absence of the Chairman of the Board and Vice Chairman of the Board, the President shall preside at all meetings of the Board
of Directors and of the stockholders at which he or she shall be present. The President shall be the chief executive officer and shall
have general charge and supervision of the business of the Corporation and, in general, shall perform all duties incident to the office
of president of a corporation and such other duties as may, from time to time, be assigned to him or her by the Board or as may be provided
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.07 &nbsp; <U>Vice Presidents</U>
.. The Vice President or Vice Presidents, at the request or in the absence of the President or during the President&rsquo;s inability to
act, shall perform the duties of the President, and when so acting shall have the powers of the President. If there be more than one Vice
President, the Board of Directors may determine which one or more of the Vice Presidents shall perform any of such duties; or if such
determination is not made by the Board, the President may make such determination; otherwise any of the Vice Presidents may perform any
of such duties. The Vice President or Vice Presidents shall have such other powers and shall perform such other duties as may, from time
to time, be assigned to him or her or them by the Board or the President or as may be provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.08 &nbsp; <U>Secretary</U>
.. The Secretary shall have the duty to record the proceedings of the meetings of the stockholders, the Board of Directors and any committees
in a book to be kept for that purpose, shall see that all notices are duly given in accordance with the provisions of these by-laws or
as required by law, shall be custodian of the records of the Corporation, may affix the corporate seal to any document the execution of
which, on behalf of the Corporation, is duly authorized, and when so affixed may attest the same, and, in general, shall perform all duties
incident to the office of secretary of a corporation and such other duties as may, from time to time, be assigned to him or her by the
Board or the President or as may be provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.09 &nbsp; <U>Treasurer</U>
.. The Treasurer shall have charge of and be responsible for all funds, securities, receipts and disbursements of the Corporation and shall
deposit or cause to be deposited, in the name of the Corporation, all moneys or other valuable effects in such banks, trust companies
or other depositories as shall, from time to time, be selected by or under authority of the Board of Directors. If required by the Board,
the Treasurer shall give a bond for the faithful discharge of his or her duties, with such surety or sureties as the Board may determine.
The Treasurer shall keep or cause to be kept full and accurate records of all receipts and disbursements in books of the Corporation,
shall render to the President and to the Board, whenever requested, an account of the financial condition of the Corporation, and, in
general, shall perform all the duties incident to the office of treasurer of a corporation and such other duties as may, from time to
time, be assigned to him or her by the Board or the President or as may be provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10 &nbsp; <U>Other Officers</U>
.. The other officers, if any, of the Corporation shall have such powers and duties in the management of the Corporation as shall be stated
in a resolution of the Board of Directors which is not inconsistent with these by-laws and, to the extent not so stated, as generally
pertain to their respective offices, subject to the control of the Board. The Board may require any officer, agent or employee to give
security for the faithful performance of his or her duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCK</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.01 &nbsp; <U>Certificates</U>
.. Every holder of stock in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by the
Chairman or Vice Chairman of the Board of Directors, if any, or the President or a Vice President, and by the Treasurer or an Assistant
Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such holder in the
Corporation. If such certificate is manually signed by one officer or manually countersigned by a transfer agent or by a registrar, any
other signature on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile
signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate
is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at
the date of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.02 &nbsp; <U>Lost, Stolen
or Destroyed Stock Certificates; Issuance of New Certificates</U> . The Corporation may issue a new certificate of stock in the place
of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner
of the lost, stolen or destroyed certificate, or such owner&rsquo;s legal representative, to give the Corporation a bond sufficient to
indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate
or the issuance of such new certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>MISCELLANEOUS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.01 &nbsp; <U>Fiscal Year</U>
.. The fiscal year of the Corporation shall be determined by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.02 &nbsp; <U>Seal</U> .
The Corporation may have a corporate seal which shall have the name of the Corporation inscribed thereon and shall be in such form as
may be approved from time to time by the Board of Directors. The corporate seal may be used by causing it or a facsimile thereof to be
impressed or affixed or in any other manner reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.03 &nbsp; <U>Waiver of Notice
of Meetings of Stockholders, Directors and Committees</U> . Whenever notice is required to be given by law or under any provision of the
articles of incorporation or these by-laws, a written waiver thereof, signed by the person entitled to notice, whether before or after
the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice
of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the
transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the
purpose of, any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in
any written waiver of notice unless so required by the articles of incorporation or these by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.04 &nbsp; <U>Indemnification
of Directors, Officers and Employees</U> . The Corporation shall indemnify to the full extent authorized by law any person made or threatened
to be made a party to any action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact
that such person or such person&rsquo;s testator or intestate is or was a director, officer or employee of the Corporation or serves or
served at the request of the Corporation any other enterprise as a director, officer or employee. For purposes of this by-law, the term
Corporation&rdquo; shall include any predecessor of the Corporation and any constituent corporation (including any constituent of a constituent)
absorbed by the Corporation in a consolidation or merger; the term &lsquo;other enterprise&lsquo; shall include any corporation, partnership,
joint venture, trust or employee benefit plan; service &lsquo;at the request of the Corporation&lsquo; shall include service as a director,
officer or employee of the Corporation which imposes duties on, or involves services by, such director, officer or employee with respect
to an employee benefit plan, its participants or beneficiaries; any excise taxes assessed on a person with respect to an employee benefit
plan shall be deemed to be indemnifiable expenses; and action by a person with respect to an employee benefit plan which such person reasonably
believes to be in the interest of the participants and beneficiaries of such plan shall be deemed to be action not opposed to the best
interests of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.05 &nbsp; <U>Interested
Directors; Quorum</U> . No contract or transaction between the Corporation and one or more of its directors or officers, or between the
Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers
are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director
or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or
transaction, or solely because his or her or their votes are counted for such purpose, if: (1) the material facts as to his or her relationship
or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee
in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though
the disinterested directors be less than a quorum; or (2) the material facts as to his or her relationship or interest and as to the contract
or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically
approved in good faith by vote of the stockholders; or (3) the contract or transaction is fair as to the Corporation as of the time it
is authorized, approved or ratified, by the Board, a committee thereof or the stockholders. Common or interested directors may be counted
in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.06 &nbsp; <U>Form of Records</U>
.. Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute
books, may be kept on, or be in the form of, punch cards, magnetic tape, photographs, microphotographs or any other information storage
device, provided that the records so kept can be converted into clearly legible form within a reasonable time. The Corporation shall so
convert any records so kept upon the request of any person entitled to inspect the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.07 &nbsp; <U>Amendment of
By-Laws</U> . These by-laws may be amended or repealed, and new by-laws adopted, by the Board of Directors, but the stockholders entitled
to vote may adopt additional by-laws and may amend or repeal any by-laws whether adopted by them or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2218235d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black"><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">Synthetic Biologics
Announces Reverse Stock Split</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Rockville, MD,
July 15, 2022 &ndash;</B> Synthetic Biologics, Inc. (NYSE American: SYN), <FONT STYLE="background-color: white">a diversified clinical-stage
company developing therapeutics designed to treat diseases in areas of high unmet need</FONT>, announced today a reverse stock split
of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every ten (10)
shares of common stock, effective as of 12:01 a.m. (Eastern Time) on July 25, 2022 (the &ldquo;Effective Date&rdquo;). The Company&rsquo;s
common stock will begin trading on a split-adjusted basis when the market opens on July 25, 2022. The reverse stock split was authorized
by the Company&rsquo;s Board of Directors on July 11, 2022. Pursuant to the laws of the State of Nevada, the Company&rsquo;s state of
incorporation, the Company&rsquo;s Board of Directors has the authority to effect a reverse stock split without shareholder approval
if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The
Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect
the reverse stock split. The Company&rsquo;s common stock will continue to trade on the NYSE American under the stock ticker &ldquo;SYN&rdquo;
but will trade under the new CUSIP number 87164U409.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">As a result of the
reverse split, each ten (10) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common
stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from 158,437,840 shares
to 15,843,784 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="color: Black; background-color: white">The
reverse stock split is being effected to ensure that the Company can meet the per share price requirements of the NYSE American, the
Company's current listing exchange. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">No fractional shares
will be issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to a fractional share because they
hold a number of shares not evenly divisible by the 1 (one) for ten (10) reverse split ratio, will automatically be entitled to receive
an additional fractional share of the Company&rsquo;s common stock to round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The Company&rsquo;s
transfer agent, Equiniti Trust Company, which is also acting as the exchange agent for the reverse split, will send instructions to stockholders
of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so.
Stockholders who hold their shares in brokerage accounts or &ldquo;street name&rdquo; are not required to take action to effect the exchange
of their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>About Synthetic
Biologics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black; background-color: white">Synthetic
Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas
of high unmet need. The Company recently consummated the acquisition of VCN Biosciences, S.L. (VCN), which is developing a new oncolytic
adenovirus (OV) platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access
of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient&rsquo;s immune
system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within
tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment;
(2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI)
tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the
emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant
(HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under
cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website
at&nbsp;www.syntheticbiologics.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Forward-Looking
Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="color: Black; background-color: white"><I>This
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
 &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and
similar expressions, and include statements regarding our planned stock split. These forward-looking statements are based on management's
expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which
are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set
forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current
expectations include, among others, the stock split having the desired effect, the combined business of Synthetic Biologics and VCN will
be successful, Synthetic Biologics' and VCN's product candidates demonstrating safety and effectiveness, as well as results that are
consistent with prior results, the ability to initiate VCN-01 dosing in an investigator sponsored study of brain tumors at the University
of Leeds (H1 2022), initiate VCN-01 dosing in combination with mesothelin-directed CAR-T cells for pancreatic and ovarian cancer in an
investigator sponsored study at the University of Pennsylvania (H1 2022), initiate a Phase 2 study of VCN-01 in combination with standard-of-care
chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy in newly diagnosed metastatic PDAC patients (Q4 2022), initiate a Phase
2/3 trial of VCN-01 as either an adjunct to chemotherapy or a potential rescue therapy in pediatric patients with advanced retinoblastoma
(early 2023), data read out from the first cohort of the SYN-004 study in allo-HCT patients (H2 2022), the SAD and MAD studies supporting
the development of SYN-020 in multiple clinical indications and planning for the initiation of a Phase 2a study of SYN-020 (H2 2022)
; the ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment
as expected; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory
requirements, regulatory limitations relating to Synthetic Biologics' and VCN's ability to promote or commercialize their product candidates
for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of
Synthetic Biologics' and VCN's products, developments by competitors that render such products obsolete or non-competitive, Synthetic
Biologics' and VCN's ability to maintain license agreements, the continued maintenance and growth of Synthetic Biologics' and VCN's patent
estate, the ability to continue to remain well financed, and other factors described in Synthetic Biologics' Annual Report on Form 10-K
for the year ended December 31, 2021 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current
reports on Form 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes
no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black"><B>For
further information, please contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black"><B>Investor Relations:<BR>
</B>Chris Calabrese<BR>
LifeSci Advisors, LLC<BR>
ccalabrese@lifesciadvisors.com&nbsp;<BR>
917-680-5608</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>syn-20220711.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6GebOdzZR+6YkxtmB3bemK7yYsVZO9oCdnBhi2EfwG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220711" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20220711">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220711_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220711_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>syn-20220711_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>syn-20220711_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20220711.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 1T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139839698156672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 11,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNTHETIC BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm2218235-2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20220711.xsd" xlink:type="simple"/>
    <context id="From2022-07-11to2022-07-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-07-11to2022-07-11">0000894158</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-07-11to2022-07-11">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-07-11to2022-07-11">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2022-07-11to2022-07-11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-07-11to2022-07-11">2022-07-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-07-11to2022-07-11">SYNTHETIC BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-07-11to2022-07-11">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-07-11to2022-07-11">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-07-11to2022-07-11">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-07-11to2022-07-11">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-07-11to2022-07-11">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-07-11to2022-07-11">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-07-11to2022-07-11">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-11to2022-07-11">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-07-11to2022-07-11">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-07-11to2022-07-11">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-07-11to2022-07-11">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-07-11to2022-07-11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-07-11to2022-07-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-07-11to2022-07-11">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-07-11to2022-07-11">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-07-11to2022-07-11">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-07-11to2022-07-11">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-07-11to2022-07-11">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,5 [U0'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ Q4#O5-<(XSON    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ Q4#O5)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #%
M0.]4(L('R(D$  #%$0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ Q4#O5)^@&_"Q @  X@P   T
M         ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #%0.]4EXJ[
M',     3 @  "P              @ &H#P  7W)E;',O+G)E;'-02P$"% ,4
M    " #%0.]4JL0B%C,!   B @  #P              @ &1$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ Q4#O5"0>FZ*M    ^ $  !H
M     ( !\1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ Q4#O5&60>9(9 0  SP,  !,              ( !UA(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2218235-2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2218235-2_8k.htm">tm2218235-2_8k.htm</File>
    <File>syn-20220711.xsd</File>
    <File>syn-20220711_lab.xml</File>
    <File>syn-20220711_pre.xml</File>
    <File>tm2218235d2_ex3-1.htm</File>
    <File>tm2218235d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2218235-2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2218235-2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20220711_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20220711_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20220711.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20220711",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2218235-2_8k.htm",
      "contextRef": "From2022-07-11to2022-07-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://syntheticbiologics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2218235-2_8k.htm",
      "contextRef": "From2022-07-11to2022-07-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-22-080032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-080032-xbrl.zip
M4$L#!!0    ( ,5 [U14M@_L/P,  ! ,   0    <WEN+3(P,C(P-S$Q+GAS
M9+5635/;,! ]MS/]#ZJO'<5Q4J"$!(:/PF0:2@<*!2X=Q=XD&F3)2#))^NLK
MR782$A.2T/HDK]Y[NROMKMT\&,4,/8%45/"6%U2J'@(>BHCR?LN[OL*'5\?M
MMH<.]C^\1^9I?L08G5)@40.=B!"W>4_LH>\DA@8Z PZ2:"'WT UAJ;6(4\I
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M-4Y)-%U0K #FX%.56N^?EL4C25-YSP#3_H;%)G9-#&Q89\94!D4-: _DIHA
M54A8Z%R^R%&[&#H-+'!#[Q,@PW870[4X6(QTAP-)*L*0C/-(4^.610]'AM(U
M08!5G1U-%A0U=F\@+Z4<%?HP0+FD\2!,:IT?2#2;=D0J48" M)WUX2'4ON&X
M2K((IZ6?*[$MZRBB1>L:$M"N#HHA# H6R!T(3!F@N"E"O$/S3X+Y,&0:2C_
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M=B5<2+N602",1N35P?B:!,\[\CU@+]V1SE\'TQ(A+\M,T7 (G4:G4L*'$EK
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MGO\?2$<XK><D5VNE1WKMA- "RZ7)!D5QV$HP:'/.L@ID1ELL!(G)+FT591L
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MC=1X6@K*#BCH5O8R*/A4&C3<4BHW']<MGTD!V1$D"YR@""7*TV2>760Y5K#
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MQV_VDI,-'?G/DV.\6_4/@X'\?$6GOGIU<O#32_S+=V=OCU_^/U!+ P04
M" #%0.]4W>^*S, /  !/-0  %@   '1M,C(Q.#(S-60R7V5X.3DM,2YH=&WE
M6VUSVS82_JX9_0><<Y-(,Y1M.6E>;-=S?FOBJY.XMIN9?KH!24A"3!(L -I1
M?_T]NR E2I:==))KW6L_U X( HO=9W>?7="[;R[?GNYU.[MOCO>/\%/0?[N7
M)Y>GQWN[&^$GGF[4CW</WA_](BXN?SD]_GYM9 J_+8:;I1>7.E=.O%,WXMSD
MLHC"0"0NE-6C-;R(5\^:][SZY <RT^-B6U@]GO@=D4L[UOCGYMK>[L'>\:>)
MCK47KUZM#W<W#B#(V=(2L_D[XM9J6.*']^\NFZF)R8S=%@>93*[6]AX7L2MW
M=C=HQHIUVXLEJO#*[H@O/69SBH$W)20K9\<:Q,9[D_/8O<+MGKQ]+2[.#[]?
MT[D<J_]L;@[7/Y;C-;%_>OG]&I[?)?:7B[CJ@%\K]F=T&H2+39;^#B7RKLOF
M#0+?*\O%M/ 3Y74B#C0>C'7BNIW]HC!5D6#7<W6MK%/BPIOD2ER4F?;?0*D+
M(G^]JKY22Q\KY_5H>C_2#O;.H8%KG64J$F^/HF[GWU4V%</O(K&UN;4E'A>I
M=),=\CZQ0J>1."F2==%[]\O%L=C/(5,BL?7%+^_ZD5C8-\9^8POUIX-:A)N)
M]FIM3XI4DS'T2*M4))DNL$8V<![([W82DY>RF(H4!LM,J8NQ@ Q6EJJ"( [C
M#H?%B]X(;Y7T6,TIZ: S70B)$2?,2$P0$$15Y,J+0JFT5GPD9(T(>C^54R&%
MK9'A&!F.D-'M8 7ML:)S%:;*(A6F\I"P2$D@R)B;(KP1B5):<2VS2HE_;J[#
M<T6IK' 3B(+M/.T@O38DE"F4Z W[X2$-M!="N+&"9)G"J 7F;?:['9[IEJ=&
M0HU&*O%0HPC''6YM8V.YGL,TQ]+!60K&31]["C;P5F/@'M0I'F?IKY79.9XM
M<R2]>FQYL+\N+C'E,!CBL74TZ-@R<V%O " 1*T 15I"L%3R307\#F1(6H;E8
M.NU@>!R(M@5XKV 14ZK"W9(L;+O"'.(&AY25GQBK?U-IMQ-/>;4E"<6!D38E
M;1QIBV,9.]]C.&SV.*NLJV3A&3]8)),WK$'Z_<)#"_2/=^I:IC):N8NK)W4[
MNDB,+0V;MU@]>85($QR&IM8'\E.2)-AS-1JA:\RL?(#-!.$4^))E:0U0!RF"
M[$65QQC'5G--B=7P83POOM-&]UTO ;+8$^>EX\H,6K4JK>!*;+ANISY[@,9(
M9S@B C=FC^#?0:_)1!9C10<F[Y)XEF1AJR5=DL%S5:0JC?CXP3PJL<I+. A>
M6++57(G=CE\-HY6P%K=1G2 6ZZ)2(<+(5!&*:,V%F(?@0G:@\? NSG*%@=JS
M$!!K=P)<*Q]6#JO-7RP0Y ]_OC@Y:RSQ\L7P^;.?GVV^6O_S,\5#R5C[CMW"
M59FO_;3;F5F7[(IH*)/)+&@"I&H0'.<.)+?!SG:!QT!P3VD(J,;<6"-2ZP(
M:$(VF6HI;",ZUZ )[DG8EPGAMP$,,D,CLPA^ZZ+/.%\C:)"\CK*-HXF1-3E2
M]<OHV=,7T<MGF_4\0-Y0!G_Y[&GTXN6S>O3OA:$=46_]Z"G_=X]<.^).;G*Y
M@*Y6#$86BQ49* 29P#^0Q2H@PD^0YEO17U!XR)4*@S,V &#JA&SY:X5D@.CF
M9XEG(;)$ >/U8D\0HBIK,5MD&B<E$3Z%.+HN'IIF'T[4>&?@+,$;939SD\:?
M&EYW*[2LSAL7\\1+9 91@2CI#7BGN#$5RALL"0-IGP5<R%M[8T8B*T=84=-N
MA];"K'D(J/V],)XH8($H!(ZLG8Z116NV,Q0]!*,^T\19K%L(A(%H1JMBVI*
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M-S I)+^HSGY)5J6JK;!Y[6\J2W2[(+ZT?-T"F]^C=&Z,2:)1L!]PBDA$#Y[
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MI06_*2AJ9$V=!%-4)2]V/WULBK5@B 4IZ4N_<,]& E$G?J&]-:H\?1;!+4U
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M,3@R,S4M,E\X:RYH=&U02P$"% ,4    " #%0.]4QVG#A@(F  "/N@  %0
M            @ 'V+0  =&TR,C$X,C,U9#)?97@S+3$N:'1M4$L! A0#%
M  @ Q4#O5-WOBLS #P  3S4  !8              ( !*U0  '1M,C(Q.#(S
D-60R7V5X.3DM,2YH=&U02P4&      8 !@") 0  'V0

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
